Molecular determinants of HIV-1 subtype C coreceptor transition from R5 to R5X4

Hong Zhang [a,b], Damien C. Tully [a,b], Tiejun Zhang [a,b], Hideaki Moriyama [b],
Jesse Thompson [a,b], Charles Wood [a,b,*]

[a] *Nebraska Center for Virology, University of Nebraska, Lincoln, NE, USA*
[b] *School of Biological Sciences, University of Nebraska, Lincoln, NE, USA*

A B S T R A C T

The molecular mechanism(s) underlying transition from CCR5 to CXCR4 usage of subtype C viruses remain largely unknown. We previously identified a subtype C HIV-1 infected child whose virus demonstrated CXCR4 usage along with CCR5 upon longitudinal follow-up. Here we delineated the molecular determinants of Env involved in expanded coreceptor usage. Residue changes in three positions of Env V3 domain are critical for the dual tropic phenotype. These include: substitution of arginine at position 11, MG or LG insertion between positions 13 and 14, and substitution of threonine at the position immediately downstream of the GPGQ crown. Introducing these mutations into V3 region of a heterologous R5 virus also conferred dual tropism. Molecular modeling of V3 revealed a possible structural basis for the dual tropic phenotype. Determining what defines a subtype C X4 virus will lead to a better understanding of subtype C HIV-1 pathogenesis, and will provide important information relevant to anti-retroviral therapy.

© 2010 Elsevier Inc. All rights reserved.

Background

HIV-1 enters host cells through a complex and dynamic process whereby envelope (Env) glycoprotein 120 (gp120) binds sequentially to CD4 and a coreceptor, typically CCR5 or CXCR4 (Alkhatib et al., 1996; Choe et al., 1996; Deng et al., 1996; Doranz et al., 1996; Dragic et al., 1996; Feng et al., 1996). Based on coreceptor usage *in vitro*, the majority of HIV-1 variants can be classified into three categories: CCR5-using viruses were designated as R5, CXCR4-using viruses, X4, and viruses able to use both receptors, R5X4 (Berger et al., 1998). These patterns of coreceptor usage usually correspond to the phenotypes defined by the formation of syncytia in MT-2 cell line, where syncytia-inducing (SI) viruses were able to use CXCR4, while nonsyncytia-inducing (NSI) viruses used CCR5 (Bjorndal et al., 1997). Transmission of HIV-1 is, in general, associated with viruses that utilize CCR5, which predominate during the acute and asymptomatic phases of infection (Michael et al., 1997; Rana et al., 1997). Disease progression is often related to the emergence of viruses that have acquired the ability to use CXCR4 (Connor et al., 1997; Scarlatti et al., 1997). The appearance of CXCR4-using viruses was associated with an accelerated rate of loss of CD4+ T cells and a relatively rapid progression to AIDS and death (Karlsson et al., 1994; Maas et al., 2000; Richman and Bozzette, 1994; Schuitemaker et al., 1992).

Coreceptor usage and switching have been extensively studied in subtype B HIV-1 isolates. Some of the features of the Env glycoprotein involved in coreceptor usage have been revealed. It is known that HIV-1 cellular tropism and coreceptor specificity are largely determined by the third hypervariable loop (V3) of the viral gp120 glycoprotein, and distinct changes in this region and higher positive charges are associated with CXCR4 coreceptor usage among subtype B viruses (Cocchi et al., 1996; De Jong et al., 1992; Hoffman and Doms, 1999; Hung et al., 1999; Hwang et al., 1991; Pollakis et al., 2001; Shioda et al., 1991; Westervelt et al., 1992). In addition to V3, other regions in gp120, such as V1/V2 and C4, have also been implicated in CXCR4 usage (Carrillo and Ratner, 1996; Hoffman et al., 2002; Labrosse et al., 2001; Nabatov et al., 2004; Ogert et al., 2001; Pastore et al., 2006). A recent study indicated that gp41 transmembrane subunit was also involved in CXCR4 utilization (Huang et al., 2008).

Subtype C HIV-1 is currently responsible for the vast majority of new HIV-1 infections worldwide and is now the most prevalent subtype (http://www.unaids.org). In sub-Saharan Africa, subtype C HIV-1 accounts for more than 60% of infections and a significant number of infections are in infants and children (Papathanasopoulos et al., 2003). However, factors that contribute to the continuing expansion of subtype C viruses have yet to be clearly elucidated. Prior studies have suggested that CXCR4-using viruses were infrequently identified in subtype C HIV-1 infection compared to subtype B (Abebe et al., 1999; Bjorndal et al., 1999; Cecilia et al., 2000; Choge et al., 2006; Cilliers et al., 2003; McCormack et al., 2002; Morris et al., 2001; Ndung'u et al., 2006; Ping et al., 1999; Pollakis et al., 2004; Zhang et al., 2006). Consequently, molecular mechanism(s) underlying the transition from R5 to X4 usage of subtype C virus remains largely

---

* Corresponding author. Nebraska Center for Virology, School of Biological Sciences, University of Nebraska-Lincoln, Morrison Center P.O. Box 830666, Lincoln, NE 68583-0900, USA. Fax: +1 402 472 3323.
E-mail address: cwood@unlnotes.unl.edu (C. Wood).

unknown. However, with the evolving global HIV-1 epidemic, accumulating evidence has now shown that there is an increase in frequency in the detection of CXCR4-using subtype C HIV-1. A recent study from South Africa reported that CXCR4-using viruses were detected in 30% of a drug-naïve AIDS cohort, suggesting an ongoing dynamic evolution and maturing of the subtype C epidemic in South Africa (Connell et al., 2008; Michler et al., 2008). In addition, the emergence of the X4 viruses was found in about 50% of subtype C infected patients receiving partially suppressive anti-retroviral therapy (ART) (Johnston et al., 2003; Kassaye et al., 2009; Tsibris et al., 2008). This suggests that ART could promote the emergence of CXCR4-using virus. Although the sample size is relatively small in those studies, the introduction of anti-retroviral therapy is likely to change the subtype C HIV-1 epidemic in Africa and the coreceptor usage of this subtype (Johnston et al., 2003; Kassaye et al., 2009; Mosier, 2009; Tsibris et al., 2008).

To date most of the studies regarding subtype C coreceptor switching mainly focus on genetic characterization of the viruses, and only a few documented the biological properties of these viruses (Abebe et al., 1999; Bjorndal et al., 1999; Cecilia et al., 2000; Choge et al., 2006; Cilliers et al., 2003; Coetzer et al., 2006; Connell et al., 2008; McCormack et al., 2002; Michler et al., 2008; Morris et al., 2001; Ndung'u et al., 2006; Ping et al., 1999; Pollakis et al., 2004; Raymond et al., 2010; Singh et al., 2009; Zhang et al., 2006). Moreover, the prediction of coreceptor tropism was mainly derived from the quasispecies rather than cloned viruses, and the molecular determinants that could govern subtype C HIV-1 coreceptor switch have not yet been deciphered experimentally. The appearance of X4 virus has been associated with poor clinical prognosis, and treatment with CCR5 inhibitors may select for CXCR4-using viruses, therefore, determining what defines a subtype C X4 virus and phenotypic characteristics of the virus will lead to a better understanding of the factors involved in pathogenesis and disease progression of subtype C HIV-1, and will provide important information relevant to anti-retroviral therapy as well.

We have previously characterized the longitudinal variations of the HIV-1 viral envelope glycoprotein obtained from a panel of HIV-1 infected children over a four-year follow-up period, and have identified a subtype C HIV-1 perinatally infected child whose virus had demonstrated CXCR4 usage in addition to CCR5 at 48 months after birth (Zhang et al., 2006). This case provides us with an invaluable resource to study the evolution of coreceptor usage and to elucidate the molecular determinants of CXCR4 usage in the context of subtype C HIV-1 in an anti-retroviral naïve individual. To understand the basis for the expanded coreceptor usage, here we analyzed the sequence variations of the viral Env from the longitudinal follow-up samples and identified the molecular determinants of subtype C HIV-1 coreceptor transition from R5 to R5X4.

Results

Variants with distinct changes in the Env V1–V5 regions appeared at the time of detection of the virus with the expanded coreceptor usage

Child 1690 was found to be HIV-1 positive at 12 months after birth and anti-retroviral naïve throughout the study. The R5 coreceptor tropism was maintained at 12, 24, 36 and until 42 months after birth; after which, the viral isolate from 48 months was found to use CXCR4 in addition to CCR5, and infected both macrophages and MT-2 T lymphoblasts where it formed syncytia [(Zhang et al., 2006) and data not shown]. We further tested the coreceptor preference of the primary isolates from 42 and 48 months in U373-MAGI indicator cells which express CD4 and either CCR5 or CXCR4. The 48-month isolate was able to infect either CCR5 or CXCR4-expressing cells, whereas the 42-month isolate only exhibited CCR5-mediated infection (Fig. 1). In order to identify the molecular determinants of the expanded coreceptor usage of the 48-month isolate, we analyzed changes of the

Fig. 1. Coreceptor usage of HIV-1 quasispecies from 42 and 48 months after birth of child 1690. The infectivity mediated by the 42 or 48-month viral isolates was measured in U373-MAGI target cells expressing CD4 and either CCR5 or CXCR4. Infection with virus SF128A, NL4-3 or 89.6 served as controls for CCR5, CXCR4 or CCR5/CXCR4 usage virus, respectively. The results are representative of two independent experiments, and the error bars represent standard deviations.

viral Env sequences from 12, 24, 36, 42 and 48 months of follow-up. Sequence analysis of the Env V1–V5 region indicated that there were distinct changes in the Env glycoprotein, mainly in the V3 and V4 regions, among clonal variants before (12, 24, 36 and 42 months) and after (48 months) NSI to SI or CCR5 to CCR5/CXCR4 phenotype switch (Fig. 2 and data not shown).

We first examined the sequence of the V3 region as this region significantly influences and determines coreceptor preference of non-subtype C HIV-1. Compared to the subtype C consensus, the V3 loops of all R5 viruses from 12 and 42 months were 34 amino acids in length and contained the GPGQ motif at the crown, characteristic of HIV-1 subtype C viruses (Fig. 2A). A neutral serine (S) residue was completely conserved at position 11 among 12 or 42-month variants. Sequence analysis of 48-month variants indicated that 46% of sequences (13 of 28 clones sequenced) harbored the V3 region sequences which are similar to those of 12 or 42-month variants, with a net charge of +5 in the V3 region, indicative of R5 usage (Fig. 2A). However, the remaining 54% of sequences (15 of 28 clones) of 48-month variants showed distinct changes in the V3 loop. Notably, an insertion of two amino acids — either MG or LG upstream of the GPGQ crown (between positions 13 and 14) was observed. In addition, mutations within the V3 region of these 48-month variants also include the change at position 11 from a neutral serine to a positive arginine (R), which was reported to associate with CXCR4 usage of subtype B HIV-1, and resulted in an increased positive charge (+6). Moreover, we also identified changes immediately downstream of the GPGQ crown from a valine (V) or alanine (A) to threonine (T). Interestingly, all the changes in the V3 domain as described previously were linked to each other in 54% of sequences (15 of 28 clones) from 48-month variants, indicating possible functional association of these changes. Based on these observations, we anticipated that a mixture of R5 and either dual R5X4 or X4 variants could co-exist in the 48-month variants.

Moreover, we also determined whether non-V3 regions also possessed unique sequences suggestive of expanded coreceptor usage. Sequence analysis showed that there were some specific changes in the V4 region which co-evolved with the changes in the V3 region. In particular, a loss of a potential N-linked glycosylation site at the N-terminal of V4 region (mainly from NTS to NTA) was noted in all but one (14 out of 15 clones, 93%) variants which have predicted R5X4 or CXCR4 usage based on V3 sequence analysis (Fig. 2B). This N-linked glycan was completely conserved in 12-month sequences and maintained in the majority of the 42-month sequences and 48-month variants with

A

V3 amino acid sequences

	11	25	Net charge	# aa	11/25	Biotype
C_CON	CTRPNNNTRKSIR--IGPGQTFYATGDIIGDIRQAHC		+4	35	S/D	R5
12m_CON	.I..G.........--.....A..-...N..........		+5	34	S/N	R5
42m_CON	.V.LG.........--.....V..-...N..........		+5	34	S/N	R5
48m_(8/28)	.V.LG.........--.....V..-...N..........		+5	34	S/N	R5
48m_(5/28)	.V..G.........--.....A..-...N..........		+5	34	S/N	R5
48m_(10/28)	.V..G.....R..MG........-..N..........		+6	36	R/N	R5X4 or X4
48m_(5/28)	.V..G.....R..LG........-..N..........		+6	36	R/N	R5X4 or X4

B

	V4
12m_CON	NTS
42m_CON	NTS
48m (11/13 without MG/LG insertion in V3)	NTS
48m (11/15 with MG/LG insertion in V3)	*NTA*
48m (3/15 with MG/LG insertion in V3)	*DTS*

Fig. 2. Comparison of sequences from child 1690 at different time points. A. Consensus V3 amino acid sequence for variants at 12 and 42 months (12m_CON and 42m_CON), respectively. Predicted V3 sequence for variants at 48 months (48m) with the number in parenthesis indicating the number of clones that contain the specific signature sequence. In all cases the sequences are compared to a HIV-1 subtype C consensus sequence. B. Comparison of the potential N-linked glycosylation site at the N-terminal of the V4 region. The loss of this glycan among all but one (14 out of 15) of the 48-month variants which have predicted CXCR4 usage based on V3 sequence analysis is in italics.

predicted CCR5 utilization based on V3 sequence analysis (Fig. 2B). These findings on the association of the linked changes in the V3 and V4 regions suggest a possible functional relationship between the V3 and V4 regions.

Coreceptor usage of the molecularly cloned chimeric viruses

To test whether the characterized Env sequences possess the predicted coreceptor usage, we created chimeric proviral constructs by introducing subtype C Env V1–V5 fragments from child 1690 into a proviral expression vector with the subtype B (NL4-3) backbone. Multiple representative Env clones with the signature sequences as described previously were selected from time points at 42 and 48 months before and after the expanded coreceptor usage.

The coreceptor usage of the resulting representative chimeras was evaluated in indicator Ghost 3 cells. Infection with virus SF128A, NL4-3 or 89.6 served as controls for CCR5, CXCR4 or CCR5/CXCR4-using virus, respectively. The CXCR4 usage of the virus was confirmed by syncytium formation in MT-2 cells. Consistent with what we observed for the primary isolates, chimera 42m-74 which contains Env V1–V5 signature sequences from 42-month time point exhibited CCR5 tropism and did not form syncytia in MT-2 cells (Fig. 3). In contrast,

chimeras derived from 48-month viral sequences bearing insertions in V3 and other linked changes in the V3 and V4 regions as described previously (48m-7 and 48m-18) caused syncytia in MT-2 cells and could infect both CXCR4 and CCR5-expressing target cells (Fig. 3). However, Env chimeras which failed to infect MT-2 cells but could infect CCR5-expressing target cells were also identified among 48-month Env derivatives (Fig. 3, 48m-30). As expected, the CCR5-using 48-month chimeras share similar signature sequences with the 42-month chimeras (Fig. 3, 42m-74 versus 48m-30). Taken together, our phenotypic analyses of the 48-month sample revealed heterogeneous viral populations comprising both R5 and R5X4 tropic variants.

We further confirmed the coreceptor usage of the representative variants by infecting TZM-bl cells, which express both coreceptors, in the presence of a CXCR4 or CCR5 inhibitor (Fig. 4A). Infection of TZM-bl cells by control NL4-3 was efficiently blocked by the CXCR4 antagonist AMD3100 and unaffected by CCR5 inhibition, as expected for a CXCR4-dependent strain. In contrast, SF128 A was not affected by CXCR4 blockade but was blocked by the CCR5 antagonist TAK 779, as expected for an R5 strain. Consistent with observations by others (Maeda et al., 2008), the dual tropic virus 89.6 was efficiently inhibited by AMD 3100 but not by TAK 779. Variants 18 and 7 from 48-month follow-up were almost completely blocked by the CCR5

		Syncytia	Ghost/CD4+	
Virus	V3 amino acid sequence	MT-2	CCR5	CXCR4
42m-74	CVRLGNNTRKSIR--IGPGQVFYTNNIIGDIRQAHC	−	+	−
48m-30	..................--.....................	−	+	−
48m-7	...P......R..MG.....T................	+	+	+
48m-18	...P......R..MG.....T................	+	+	+
SF128A		−	+	−
NL4-3		+	−	+
89.6		+	+	+

Fig. 3. Amino acid comparison of the V3 sequences and coreceptor utilization of the representative viruses from 42 and 48 months. Chimeric viruses and controls were produced by transfection of 293 T cells. An equal quantity of $TCID_{50}$ for each virus was added to Ghost 3 cells expressing the indicated coreceptors. GFP expression induced by Tat activation of the integrated LTR-GFP cassette was used to assign positive or negative value after fluorescent microscopic examination at day 4 post-infection. MT-2 infection was monitored for syncytia formation at day 6 post-infection. Infection with virus SF128A, NL4-3 and 89.6 served as controls for CCR5, CXCR4 or CCR5/CXCR4 usage virus, respectively. Residue changes in the three positions that may affect the coreceptor usage are indicated by arrows.

A. TZM-bl

B. U373-MAGI-CCR5

C. U373-MAGI-CXCR4

Fig. 4. Coreceptor preference of representative chimeric proviruses. A. Coreceptor usage of 42-month and 48-month variants of child 1690 was determined by entry inhibition into TZM-bl cells with 1 μM CXCR4 inhibitor (AMD 3100) or CCR5 inhibitor (TAK-779). Viruses SF128A, NL4-3 and 89.6 served as controls for CCR5, CXCR4 or CCR5/CXCR4 usage virus, respectively. B, C. Infection and blocking with cognate coreceptor inhibitor were performed in U373-MAGI-CCR5 (B) or U373-MAGI-CXCR4 (C) cells. Viruses SF128A, NL4-3 and 89.6 served as controls for CCR5, CXCR4 or CCR5/CXCR4 usage virus, respectively. The data are expressed as mean values from experiments performed in triplicate, and the error bars indicate standard deviations.

inhibitor and were also inhibited by the CXCR4 blockade but less efficiently (70% inhibition), suggesting the dual CCR5/CXCR4 usage. In contrast, similar to 42-month variant 74, variant 30 from 48-month follow-up was essentially fully blocked by TAK 779 but not affected by AMD 3100, resembling the R5 phenotype (Fig. 4A). The dual tropic phenotype of variant 48m-18 was reinforced by the infection and blocking experiments in U373-MAGI indicator cells, where the virus was able to infect either CCR5 or CXCR4-expressing cells, and was completely inhibited by the cognate coreceptor inhibitor with the respective cell lines (Figs. 4B and C). Whereas, variant 48m-30 consistently showed CCR5-dependence as indicated by an effective inhibition of infection in U373-MAGI-CCR5 cells by TAK 779 (Fig. 4B).

V3 domain is necessary and sufficient to confer the expanded coreceptor usage of the 48-month isolate

Our sequence analyses have indicated that some potential sites in V3 and V4 regions may be involved in the expanded coreceptor usage of the 48-month isolate. To better understand the impact of the V3 and V4 regions on coreceptor switch, we constructed chimeric *env* clones by exchanging the V3 or V4 region between the 48-month dual CCR5/CXCR4-using variant 48m-18 and CCR5-using variant 48m-30 (Fig. 5A). The coreceptor usage of the resulting chimeras was evaluated by infection assays using Ghost 3 cells and MT-2 cells as described previously. We found that the chimera 30-V3-18 which contains the V3 region from R5-tropic variant 48m-30 in the context of R5X4 *env* backbone (variant 48m-18) failed to infect CXCR4-

expressing target cells, did not form syncytia in MT-2 cells, and only exhibited CCR5 tropism (data not shown). This suggests that the V3 domain of 48m-30 confers the CCR5 coreceptor usage.

We further tested the specificity of coreceptor usage of the chimera 30-V3-18 by infecting TZM-bl cells in conjunction with CXCR4 and CCR5 inhibitors. Infection with virus SF128A, NL4-3 or 89.6 served as controls for CCR5, CXCR4 or CCR5/CXCR4-using virus, respectively. Similar to the parental R5X4 variant 48m-18, the infection of TZM-bl cells by the chimera 30-V3-18 was essentially fully blocked by the CCR5 antagonist TAK 779 (Fig. 5B). However, the infection was not blocked by the CXCR4 antagonist AMD 3100, similar to that of the parental CCR5-using variant 48m-30 (Fig. 5B). We therefore concluded that V3 domain is necessary and sufficient to confer the expanded coreceptor usage of 48m-18. In contrast, the chimera 30-V4-18, that contained the V4 region from R5-tropic variant 48m-30 in the context of R5X4 *env* backbone of variant 48m-18 remained R5X4 tropic, suggesting that V4 region is not essential for the expansion of coreceptor usage of the variant 48m-18 (Fig. 5B).

Infection of U373-MAGI target cells with the domain-exchanged chimeras provided additional evidence of the Env V3 domain as a major determinant of R5X4 usage. As shown in Fig. 5C, the chimera 30-V3-18 only displayed CCR5-mediated infection in CCR5-expressing target cells, albeit less efficient than the parental R5 tropic variant 48m-30. In contrast, the V4 domain-swapped chimera 30-V4-18 mediated similar level of infection in either CCR5 or CXCR4-expressing cells compared to the parental dual tropic virus 48m-18 (Fig. 5C).

Fig. 5. The impact of the V3 and V4 regions on the coreceptor usage. A. Schematic representation of the V3 or V4 domain-swapped chimeras. V3 or V4 region from R5 clone 48m-30 was introduced into the *env* backbone of R5X4 clone 48m-18 to generate the domain-swapped chimeras 30-V3-18 or 30-V4-18. The coreceptor utilization of each virus is indicated. B. Coreceptor usage of the 48-month parental variants (48m-30 and 48m-18) and *env* chimeras (30-V3-18 and 30-V4-18) was determined by entry inhibition into TZM-bl cells with 1 μM CXCR4 inhibitor (AMD 3100) or CCR5 inhibitor (TAK 779). Viruses SF128A, NL4-3 and 89.6 served as controls for CCR5, CXCR4 or CCR5/CXCR4 usage virus, respectively. C. The infectivity mediated by the 48-month parental variants and the V3 or V4 domain-swapped chimeras was measured in U373-MAGI target cells expressing CD4 and either CCR5 or CXCR4. Infection with virus SF128A, NL4-3 or 89.6 served as controls for CCR5, CXCR4 or CCR5/CXCR4 usage virus, respectively. The results are representative of three independent experiments, and the error bars represent standard deviations.

Changes in three amino acid residues of the Env V3 region are required for the expanded coreceptor usage

To identify the molecular determinants of CCR5/CXCR4 utilization, we performed site-directed mutagenesis to change the residues at the three positions (R, MG and T) in the V3 region of variant 48m-18 to resemble the amino acids observed in the R5 variants as shown in Fig. 6A. Since A and V co-existed among the R5 variants at similar frequency, we changed T to A for the convenience of mutagenesis. The coreceptor usage of each resulting mutant was first evaluated in Ghost 3 cells and MT-2 cells. Notably, when single or combinations of mutations in the V3 region were introduced, all the mutants failed to infect CXCR4-expressing target cells, and only exhibited CCR5 tropism. This is consistent with the observations that none of the mutants was able to form syncytia in MT-2 cells (Fig. 6A).

We further analyzed the infection of these mutants in U373-MAGI cells (Fig. 6B). As expected, the infection of all the mutants in 373-

MAGI-CXCR4 cells was abrogated. Therefore, we conclude that, in the context of the 48m-18 V3 loop, the presence of R, MG and T was critical for envelope interaction with CXCR4 coreceptor, and the residues at those three positions are the minimal determinant for the CXCR4 usage.

Positively selected sites

To directly examine the molecular evolution of HIV-1 in the context of coreceptor usage, we estimated the selection pressure acting across residues within the V3 domain. Only two residues showed evidence for positive selection as indicated by the rate of nonsynonymous and synonymous substitutions (dN/dS). The residue immediately downstream of the GPGQ crown, which was an A, V or T was found to have a dN/dS ratio of 7.4 ($p = 0.087$). Furthermore, an S11R substitution had a dN/dS value of 4.50 albeit with a higher probability ($p = 0.283$).

Fig. 6. Single and combinations of mutations within the V3 region of R5X4 virus 48m-18 and coreceptor utilization of the resulting V3 mutant chimeric viruses. A. GFP expression in Ghost 3 cells expressing the indicated coreceptors was used to assign positive or negative value after fluorescent microscopic examination at day 4 post-infection. MT-2 infection was monitored for syncytia formation at day 6 post-infection. Mutations in the three positions are indicated by arrows. B. Infectivity mediated by mutants containing single or combinations of mutations within the V3 region in the backbone of R5X4 virus 48m-18 was measured in U373-MAGI target cells expressing CD4 and either CCR5 or CXCR4. Infection with virus SF128A, NL4-3 or 89.6 served as controls for CCR5, CXCR4 or CCR5/CXCR4 usage virus, respectively. The results are representative of three independent experiments, and the error bars indicate standard deviations.

V3 mutations in unrelated subtype C HIV-1 have similar effect on coreceptor usage

We next evaluated whether introduction of the mutations in the three positions in the V3 region could confer the dual tropic phenotype on a different HIV-1 genetic background. We selected another HIV-1 subtype C R5 variant, 1984i48m-18, that was derived from child 1984 at 48 months after birth, and introduced those mutations into its V3 region (Fig. 7A). We found that the mutations in the V3 region enabled the virus to form syncytia in MT-2 cells (Fig. 7A) and infect CCR5 or CXCR4-expressing target cells (Fig. 7B). Thus, the presence of R, MG and T in the V3 region also conferred the dual tropism in a heterologous viral context.

V3 sequence comparison between the R5X4-using viruses in the present and published studies

To address the biological relevance of our findings, and to further validate and confirm our results indicating that the V3 region is a major determinant for coreceptor usage of subtype C viruses, we compared the sequences of our R5X4 virus with those of subtype C R5X4 or X4 virus in the HIV-1 database or published literature to see whether the amino acids of interest are conserved. Sequence comparison revealed a strong homology in the V3 domain between our R5X4 virus and the published dual tropic or X4 tropic virus

(Fig. 8). The two amino acid insertions upstream of the GPGQ crown (between positions 13 and 14) and the amino acid substitution of T immediately downstream of the GPGQ crown (position 21) were present in the majority of the sequences of R5X4 and X4 viruses. Nineteen of the 36 dual tropic viruses (53%) had the two amino acid insertions, mainly IG, and 17 of the 36 viruses (47%) had the threonine substitution (Fig. 8A). A similar frequency in those changes was also observed for the X4 viruses, with 59% of X4 viruses (22 in total) harboring the two residue insertions and 50% of the viruses having the threonine substitution, respectively (Fig. 8B). The high sequence similarity in the V3 region among those CXCR4-using viruses indicated that the V3 region could be a major determinant that governs the coreceptor usage in a majority of the subtype C viruses with CXCR4 usage. Another important feature in the V3 region associated with CXCR4 usage is the arginine substitution in the GPGQ crown, mainly at position 18 or 20 (Figs. 8A and B) although this residue substitution is absent from our dual tropic viruses.

Molecular modeling of V3 structure

To evaluate the possible influences of those mutations observed in the V3 region on the structure of V3 in the context of gp120, we introduced the sequences of the 48-month dual tropic variant 48m-18 and CCR5-using variant 48m-30 into the X-ray crystal structures of V3-containing gp120 core (Huang et al., 2005), respectively (Fig. 9).

A

Virus	V3 amino acid sequence	Syncytia
		MT-2
1984i48m-18	CTRPNNNTRKSIR--IGPGMAYFATGNIIGDIRQAHC	-
1984i48m-18RMGT	..........R..MG.....T................	+
SF128A		-
NL4-3		+
89.6		+

B

Fig. 7. Effects of V3 mutations on coreceptor usage of unrelated subtype C HIV-1. A. The predicted V3 amino acid sequences of a 48-month variant of child 1984 and the V3 mutant. MT-2 infection was monitored for syncytia formation at day 6 post-infection. B. The coreceptor utilization of the 48-month parental variant and the V3 mutant was determined in U373-MAGI target cells expressing CD4 and either CCR5 or CXCR4. Infection with virus SF128A, NL4-3 and 89.6 served as controls for CCR5, CXCR4 or CCR5/CXCR4 usage virus, respectively. The results are representative of two independent experiments, and the error bars represent standard deviations.

Our structural model demonstrated that the MG insertion in variant 48m-18 could increase the bulkiness of the V3 tip and may introduce structural stress in the V3 tip. As a result, it could disrupt the hydrogen bond between F317 and R308, and the hydrogen bond between F317 and Y318, thereby changing the rigidity and increasing the flexibility of the V3 tip (Fig. 9E).

We further compared the surface electrostatic potential of the two variants with different coreceptor preference (Figs. 9C–D, F–G). An extended positively charged area was observed in the V3 tip of the dual tropic variant 48m-18 due to the substitution of the positively charged arginine at position 306 (Figs. 9F versus C). In addition, a negatively charged cavity on the other side of the V3 tip, resulting from the MG insertion, was also apparent in the R5X4 variant 48m-18 compared to the R5 variant 48m-30 (Figs. 9G versus D). Therefore, the differences in the flexibility and charge distribution of the V3 tip may account for the observed coreceptor preference of these two variants.

Fig. 8. Sequence variation in the V3 region of HIV-1 subtype C R5X4 and X4 viruses from HIV-1 database and published literature. The X axis indicates the amino acid position, whereas the symbol height (Y axis) indicates the relative frequency of each amino acid at that position of 36 R5X4 viruses (A) and 22 X4 viruses (B).

Fig. 9. V3 sequence and structure modeling. A. Alignment of V3 sequence of HXB2, 48m-30 and 48m-18 variants. The numbering of the gp120 residues corresponds to that of HXB2. The two residue insertions in 48m-18 are colored red. B–G. V3 structures of the R5 variant 48m-30 (B–D) and the dual tropic variant 48m-18 (E–G) are modeled with Swiss-Model (http://swissmodel.expasy.org) using 2B4C as the template (Huang et al., 2005). The protein backbone models show structural differences between variants 48m-30 (B) and 48m-18 (E). The insertions in 48m-18 are indicated by red annotation (M309 and G310). Hydrogen bonds within backbone atoms are indicated by the orange dashed lines. The asterisks indicate the hydrogen bonds lost in 48m-18 but present in 48m-30. The surface models show the electrostatic force distribution of variants 48m-30 (C, D) and 48m-18 (F, G). The models B and C or E and F are in the same view angles. Models D and G are rotated 180° about the vertical axis. The scale of the electrostatic forces is between −2.000 (red, negative charge) and +2.000 (blue, positive charge). The white area represents neutral charge.

Discussion

The pathogenic significance of coreceptor switch in HIV-1 infection is not completely understood. This situation is more complex in subtype C infection as limited information is available, especially regarding longitudinal isolates that showed coreceptor switching over time. In this study, we generated a set of molecularly cloned viruses from an infected child and delineated the molecular feature for the transition from CCR5 to dual CCR5/CXCR4 utilization of subtype C variants during longitudinal follow-up. However, we were not able to follow up the child beyond 48 months to determine whether the virus had eventually become exclusively X4 tropic.

The central role of the V3 loop in HIV-1 coreceptor usage has been well established for subtype B viruses. However, the genetic determinants associated with subtype C coreceptor utilization have not been defined at the clonal level, although several studies have described the potential molecular features, particularly in the V3 domain, that could influence subtype C virus coreceptor tropism (Cilliers et al., 2003; Coetzer et al., 2006; Raymond et al., 2010; Singh et al., 2009). Our study, by swapping the V3 loop between the CCR5 and dual tropic variant, clearly indicated that consistent with non-subtype C viruses, V3 loop is a principal determinant for coreceptor usage of subtype C viruses. Therefore, the key role of V3 loop in governing HIV-1 coreceptor utilization could be a common mechanism among different subtypes, although regions other than V3 loop could also be involved in this process. In addition, we found that in the context of the dual tropic virus, V4 region is not essential for the expanded coreceptor usage. But it is possible that the co-evolving residues in V4 may act as compensatory or stabilizing mutations to accommodate some of the functional constraints imposed by the

sequence variation observed in V3. Alternatively, the variations in V4 could directly or indirectly influence other biological properties of the Env. The significance of the co-variation of the V3 and V4 domains is currently under investigation.

We further analyzed the residues within V3 domain that were critical for the R5X4 dual tropic phenotype of the subtype C viruses. Different rules of estimating coreceptor tropism have been published based on the amino acid sequence of the Env V3 region. Among these, the most widely used is the 11/25 rule, where acquisition of positively charged residues at either amino acid position 11 or 25 in V3 was associated with CXCR4 usage (De Jong et al., 1992; Milich et al., 1997). Recently, bioinformatics driven prediction systems have been developed (Jensen et al., 2006, 2003). In this study, we found that a positively charged residue arginine was present at position 11 of the dual tropic variants. However, this positively charged residue is important (Fig. 6B, mutant 48m-18-S) but not sufficient (Fig. 6B, mutant 48m-18-ΔMGA) for CXCR4 utilization in the context of the variant 48m-18. In addition, the positively charged residue at position 25 was absent in all of the variants having the predicted dual tropic phenotype including 48m-18. Consistent with reports for subtype B (Fouchier et al., 1992; Shioda et al., 1994), we observed a correlation between the increased positive charge of V3 loop and CXCR4 tropism, with the CXCR4-using viruses having higher positive charge (+6) compared to CCR5-using viruses (+5), suggesting a possible common feature for coreceptor switch among viruses from different subtypes. The second significant change in the V3 region contributed to CXCR4 usage was the insertion of either MG or LG between positions 13 and 14. Removal of this insertion abolished CXCR4 utilization by the virus (Fig. 6B), indicating the critical role of this insertion in the dual coreceptor tropism of subtype C viruses. One or two amino acid

insertions at the same location have been observed in other studies on subtype C X4 viruses (Cilliers et al., 2003; Coetzer et al., 2006; Raymond et al., 2010; Singh et al., 2009), but our study is the first to experimentally verify the significance of the insertions for the expanded CXCR4 tropism. Another genetic feature in the V3 region related to the dual tropic subtype C viruses was the amino acid substitution by T immediately downstream of the GPGQ crown. Similar to the other two mutations, this residue is required but insufficient in conferring the dual tropism of the viruses (Fig. 6B). The importance of this amino acid substitution in determining coreceptor preference has not been indicated in previous studies. However, A-to-T substitution has been implicated in escape from certain neutralizing antibody (Reitz et al., 1994), and also found to contribute to the acquired replication in the thymus in vivo but not in macrophage (Miller et al., 2001). Interestingly, our selection analysis revealed that the amino acid substitution by T at this position was under strong positive selection, with an estimated dN/dS value of 7.4, suggesting that the presence of T at this site may be essential for the binding to both CCR5 and CXCR4. Therefore, the three mutations in the V3 region (R, MG and T) collectively contribute to CXCR4 engagement. More importantly, introducing the three mutations into a heterologous subtype C R5 variant was also sufficient in imparting the expanded CXCR4 tropism.

It has been suggested that coreceptor switching occurs less frequently for subtype C viruses compared to subtype B viruses. The intrinsic differences in V3 conformation between the two subtypes could be responsible for the limited CXCR4 adaptation for subtype C virus (Patel et al., 2008). It is also possible that the more complex genetic pathway with more than one mutation sites needed for efficient CXCR4 usage, as indicated in this study and those of others (Cilliers et al., 2003; Coetzer et al., 2006; Raymond et al., 2010; Singh et al., 2009), may also contribute to the infrequent CXCR4 usage of subtype C viruses.

The structural basis for CCR5 or CXCR4 specificity is still poorly understood. The current model of how gp120 interacts with CCR5 suggests that the tip of V3 region of gp120 binds to the second extracellular loop (ECL2) of CCR5, the base and stem of V3 and bridging sheet binds to the N-terminus of CCR5 (Cocchi et al., 1996; Cormier and Dragic, 2002; Huang et al., 2007, 2005; Rizzuto et al., 1998). The involvement of ECLs and the N-terminal of CXCR4 in the binding of CXCR4 was also observed (Brelot et al., 1999; Doranz et al., 1999; Kajumo et al., 2000; Wang et al., 2004). In this study, the mechanism by which the three mutations in the V3 loop determine CXCR4 usage is unclear. It is possible that the structural alterations created by MG insertion in the V3 tip may affect the interaction of the V3 tip with ECL2 of CCR5, and as a compensation of this, the insertion could potentially change the reliance of V3 base and bridging sheet of gp120 on the CCR5 N-terminus for entry. On the other hand, the changes in the structure that affect how V3 recognizes CCR5 may impart a more flexible conformation to the virus. This flexibility may be essential for engaging CXCR4 as an alternative coreceptor while retaining its ability to interact with CCR5. It has been suggested that dual tropic HIV-1 strains may have extreme flexibility to display two different conformations (Cardozo et al., 2007) or binding sites (Hartley et al., 2005; Nolan et al., 2008) on the V3 surface in order to interact with either CCR5 or CXCR4. Our surface electrostatic potential analysis appeared to support this notion by showing the presence of both a negative cavity and a strong positively charged V3 tip in the dual tropic variant 48m-18. The positively charged surface may interact with the unusually anionic surface of CXCR4 (Brelot et al., 1999). On the other hand, the negative cavity in V3 seems to be consistent with the proposed negatively charged or neutral nature of R5 tropic viruses (Basmaciogullari et al., 2002; Cardozo et al., 2007; Hartley et al., 2005). Further dissecting the possible impact of the adapted changes associated with the expanded coreceptor utilization on the ability of V3 to interact with CCR5 or CXCR4 will provide

important information on the molecular mechanisms and the structural basis for subtype C HIV-1 coreceptor usage.

In summary, our study provides strong evidence for the molecular determinants of subtype C HIV-1 dual coreceptor tropism. Specific changes in three areas in the V3 domain including residue substitutions or insertions account for the transition from a R5 to R5X4 phenotype. In addition, the increased net charge in V3 is another feature coupled with the CXCR4 utilization. Our structural modeling suggested that possible structure alterations in V3 resulted from those sequence changes, and thus enabling the virus to adopt the structure required for the R5X4 phenotype. Although this is the only case of expanded coreceptor usage that was identified among our Zambian mother–infant cohort, to our knowledge our study is the first to use cloned viruses to experimentally decipher the molecular determinants of the expanded CXCR4 tropism of subtype C HIV-1 since previous studies are limited to sequence analyses only. In addition, our study suggested that the presence of the three mutations in the V3 region may also affect coreceptor usage of other subtype C viruses. Moreover, the strong homology in the V3 region, particularly the two amino acid insertions and the T substitution, between our R5X4 tropic virus and the published subtype C dual or X4 tropic virus sequences further strengthens our conclusions and reinforces the impact of these mutations on CXCR4 preference of subtype C viruses. With more subtype C X4 viruses being identified, particularly with the emerging availability of entry inhibitors, more detailed studies on virological adaptations within subtype C viruses associated with the acquired ability to use CXCR4 as a coreceptor will be needed to further elucidate the molecular mechanisms controlling coreceptor preference. The panel of genetically related but functionally distinct chimeric viruses should be useful tools in understanding how specific changes in the Env V3 domain favoring coreceptor switch may affect the biological properties of the virus, and contribute to the pathogenesis of subtype C HIV-1.

Materials and methods

Cells

293 T, TZM-bl, MT-2, and Ghost 3 or U373-MAGI cell lines which express specific coreceptor were obtained from the NIH AIDS Research and Reference Reagent Program. 293 T and TZM-bl cells were maintained in Dulbecco's modified Eagle medium (DMEM) with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 µg/ml streptomycin. MT-2 cells were maintained in RPMI 1640 medium with 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin. Ghost 3 cells expressing CD4 and either CCR5 or CXCR4 were maintained in DMEM with 10% FBS, 500 µg/ml G418, 100 µg/ml hygromycin B, penicillin–streptomycin and 1.0 µg/ml puromycin. U373-MAGI-CCR5 and U373-MAGI-CXCR4 cells were propagated in selection medium consisting of DMEM supplemented with 10% FBS, 200 µg/ml G418, 100 µg/ml hygromycin B and 1.0 µg/ml puromycin. Culture medium for virus infection and inhibition assays consisted of DMEM with 10% FBS.

Env cloning, plasmid construction, and mutagenesis

The existing, genetically characterized Env V1–V5 clones from child 1690 were the source of genetic materials for generation of the Env chimeras (Zhang et al., 2006). Multiple representatives of Env clones with the signature sequences were selected from time points before (42 months) and after (48 months) coreceptor switch. The chimeric Env expression construct or proviral expression construct containing patient-derived Env V1–V5 region was generated as described previously (Zhang et al., 2010). Briefly, Env V1–V5 fragment from those selected clones was first introduced into an Env expression vector, pSRH NLA/S/Av, with the subtype B (NL4-3) backbone. All the

patient-derived chimeric Env expression constructs were first screened for biological function using the fusion assay as described previously (Zhang et al., 2010). Finally, the functional envelope construct was transferred into a proviral expression vector-pNL4-3 A/S/Av, with NL4-3 viral backbone, resulting in the infectious molecular clones.

Single and combinations of mutations within V3 region of the virus were introduced by site-directed mutagenesis using QuickChange II XL kit (Stratagene). All procedures were performed according to the manufacturer's protocol. The V3 or V4 region chimeras were generated by overlapping PCR. Finally, the pSRH NLA/S/Av envelope construct of a serial of mutants was transferred into the proviral expression vector-pNL4-3 A/S/Av to generate the infectious molecular clones. The sequences of the resulting chimeras were confirmed by sequence analysis to ensure that only the desired substitutions were present.

Infectious HIV-1 viral stocks

Wild-type or mutated infectious molecularly cloned viral stocks were produced by transfection of 293 T cells with relevant proviral constructs. Nine micrograms of proviral constructs was transfected into 2.2×10^6 293 T cells using Fugene 6 (Roche). The resulting infectious viruses were harvested 48 h post-transfection. Tissue culture dose for 50% infectivity ($TCID_{50}$) was determined for each virus in TZM-bl cells. Viral titer was defined as $TCID_{50}/ml$.

Determination of viral coreceptor utilization

The coreceptor utilization of these mutated chimeric viruses was first tested in Ghost 3 cells that express CD4 and specific coreceptor, either CCR5 or CXCR4. These cells contain HIV-2 LTR promoter cassettes that express green fluorescent protein (GFP) in response to stimulation with HIV-1 Tat. Equivalent infectious units, 400 $TCID_{50}$, of each chimeric provirus from transfected 293T cells as described previously were added to triplicate wells in a 24-well plate containing 4×10^4 Ghost cells per well. Ghost cells were assayed for infection by the observation of GFP expression at 4–5 days post-infection. The CXCR4 utilization was confirmed by the appearance of syncytia in MT-2 cells. For MT-2 infection, 500 $TCID_{50}$ of each chimeric provirus was added to triplicate wells in a 24-well plate containing 5×10^4 MT-2 cells per well. On days 6–7 post-infection, cells were scored for syncytia formation.

Entry inhibition assays

Entry inhibitors TAK 779 or JM-2987 (hydrobromide salt of AMD 3100) were obtained from the NIH AIDS research and Reference Reagent Program. Entry inhibition was examined in TZM-bl or U373-MAGI-CCR5 or CXCR4 indicator cells in 96-well plates. Briefly, the cells were pre-treated with 50 µl of 2 µM of TAK 779 or AMD 3100 for 30 min at 37 °C before infection. One hundred fifty $TCID_{50}$ of each virus (in 50 µl) was then added to TZM-bl cells in triplicate for 72 h at 37 °C or 100 $TCID_{50}$ of each virus was added to U373-MAGI-CCR5 or CXCR4 cells in the presence of 10 µg/ml of DEAE-dextran for 48 h at 37 °C. At the end of the culture period, the cells were lysed and processed for luciferase activity (Luciferase Assay System, Promega, Madison, WI) in TZM-bl cells or β-galactosidase activity (Galaco-Star System, Applied Biosystems, Bedford, MA) in U373-MAGI-CCR5 or CXCR4 cells. The percentage of entry inhibition was calculated by the luciferase or β-galactosidase activity in the presence of the entry inhibitor relative to that in the absence of inhibitor. Background luminescence in uninfected wells was subtracted from all experimental wells.

Infection assays

One hundred fifty $TCID_{50}$ of each virus was used to infect 1×10^4 U373-MAGI-CCR5 or CXCR4 cells in triplicate in the presence of 10 µg/ml of DEAE-dextran in a 96-well plate. At 48 h post-infection, the infection was quantified by measuring β-galactosidase activity as described previously.

Positive selection analysis

To identify selection on individual codons within V3, we computed the mean ratio of nonsynonymous to synonymous nucleotide substitutions (dN/dS) per site using the single-likelihood ancestor counting (SLAC) method available in the Datamonkey web interface of the HY-PHY package (Pond and Frost, 2005; Pond et al., 2005). In each case, this analysis utilized the GTR model of nucleotide substitution and an input neighbor-joining tree.

Structure modeling of the V3 loop

Structure modeling of the V3 loop for the R5 variant 48m-30 and the dual tropic variant 48m-18 was performed using the SWISS-MODEL server [http://swissmodel.expasy.org/; (Arnold et al., 2006)]. The server chose the crystal structure of HIV-1 JR-FL gp120 core protein as a structural template [Protein Data Bank ID 2B4C; G chain; (Huang et al., 2005)] for both variants. The root-mean-square deviation (RMSD) between the model and the template was 0.05 Å for both coordinates.

The electrostatic potential of variants 48m-30 and 48m-18 was calculated using PBEQ Solver on CHARMM-GUI [http://www.charmm-gui.org/; (Jo et al., 2008)] by solving the Poisson–Boltzmann equation (Im et al., 1998). Model visualizations were made using PyMOL (DeLano, 2008).

References

Abebe, A., Demissie, D., Goudsmit, J., Brouwer, M., Kuiken, C.L., Pollakis, G., Schuitemaker, H., Fontanet, A.L., Rinke de Wit, T.F., 1999. HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. AIDS 13 (11), 1305–1311.

Alkhatib, G., Combadiere, C., Broder, C.C., Feng, Y., Kennedy, P.E., Murphy, P.M., Berger, E.A., 1996. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272 (5270), 1955–1958.

Arnold, K., Bordoli, L., Kopp, J., Schwede, T., 2006. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22 (2), 195–201.

Basmaciogullari, S., Babcock, G.J., Van Ryk, D., Wojtowicz, W., Sodroski, J., 2002. Identification of conserved and variable structures in the human immunodeficiency virus gp120 glycoprotein of importance for CXCR4 binding. J. Virol. 76 (21), 10791–10800.

Berger, E.A., Doms, R.W., Fenyo, E.M., Korber, B.T., Littman, D.R., Moore, J.P., Sattentau, Q.J., Schuitemaker, H., Sodroski, J., Weiss, R.A., 1998. A new classification for HIV-1. Nature 391 (6664), 240.

Bjorndal, A., Deng, H., Jansson, M., Fiore, J.R., Colognesi, C., Karlsson, A., Albert, J., Scarlatti, G., Littman, D.R., Fenyo, E.M., 1997. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J. Virol. 71 (10), 7478–7487.

Bjorndal, A., Sonnerborg, A., Tscherning, C., Albert, J., Fenyo, E.M., 1999. Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. AIDS Res. Hum. Retroviruses 15 (7), 647–653.

Brelot, A., Heveker, N., Adema, K., Hosie, M.J., Willett, B., Alizon, M., 1999. Effect of mutations in the second extracellular loop of CXCR4 on its utilization by human and feline immunodeficiency viruses. J. Virol. 73 (4), 2576–2586.

Cardozo, T., Kimura, T., Philpott, S., Weiser, B., Burger, H., Zolla-Pazner, S., 2007. Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res. Hum. Retroviruses 23 (3), 415–426.

Carrillo, A., Ratner, L., 1996. Human immunodeficiency virus type 1 tropism for T-lymphoid cell lines: role of the V3 loop and C4 envelope determinants. J. Virol. 70 (2), 1301–1309.

Cecilia, D., Kulkarni, S.S., Tripathy, S.P., Gangakhedkar, R.R., Paranjape, R.S., Gadkari, D.A., 2000. Absence of coreceptor switch with disease progression in human immunodeficiency virus infections in India. Virology 271 (2), 253–258.

Choe, H., Farzan, M., Sun, Y., Sullivan, N., Rollins, B., Ponath, P.D., Wu, L., Mackay, C.R., LaRosa, G., Newman, W., Gerard, N., Gerard, C., Sodroski, J., 1996. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85 (7), 1135–1148.

Choge, I., Cilliers, T., Walker, P., Taylor, N., Phoswa, M., Meyers, T., Viljoen, J., Violari, A., Gray, G., Moore, P.L., Papathanosopoulos, M., Morris, L., 2006. Genotypic and phenotypic characterization of viral isolates from HIV-1 subtype C-infected children with slow and rapid disease progression. AIDS Res. Hum. Retroviruses 22 (5), 458–465.

Cilliers, T., Nhlapo, J., Coetzer, M., Orlovic, D., Ketas, T., Olson, W.C., Moore, J.P., Trkola, A., Morris, L., 2003. The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J. Virol. 77 (7), 4449–4456.

Cocchi, F., DeVico, A.L., Garzino-Demo, A., Cara, A., Gallo, R.C., Lusso, P., 1996. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat. Med. 2 (11), 1244–1247.

Coetzer, M., Cilliers, T., Ping, L.H., Swanstrom, R., Morris, L., 2006. Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates. Virology 356 (1–2), 95–105.

Connell, B.J., Michler, K., Capovilla, A., Venter, W.D., Stevens, W.S., Papathanasopoulos, M.A., 2008. Emergence of X4 usage among HIV-1 subtype C: evidence for an evolving epidemic in South Africa. AIDS 22 (7), 896–899.

Connor, R.I., Sheridan, K.E., Ceradini, D., Choe, S., Landau, N.R., 1997. Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 185 (4), 621–628.

Cormier, E.G., Dragic, T., 2002. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J. Virol. 76 (17), 8953–8957.

De Jong, J.J., De Ronde, A., Keulen, W., Tersmette, M., Goudsmit, J., 1992. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J. Virol. 66 (11), 6777–6780.

DeLano, W.L., 2008. The PyMOL Molecular Graphics System. DeLano Scientific LLC, Palo Alto, CA, USA. http://www.pymol.org.

Deng, H., Liu, R., Ellmeier, W., Choe, S., Unutmaz, D., Burkhart, M., Di Marzio, P., Marmon, S., Sutton, R.E., Hill, C.M., Davis, C.B., Peiper, S.C., Schall, T.J., Littman, D.R., Landau, N.R., 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381 (6584), 661–666.

Doranz, B.J., Rucker, J., Yi, Y., Smyth, R.J., Samson, M., Peiper, S.C., Parmentier, M., Collman, R.G., Doms, R.W., 1996. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85 (7), 1149–1158.

Doranz, B.J., Orsini, M.J., Turner, J.D., Hoffman, T.L., Berson, J.F., Hoxie, J.A., Peiper, S.C., Brass, L.F., Doms, R.W., 1999. Identification of CXCR4 domains that support coreceptor and chemokine receptor functions. J. Virol. 73 (4), 2752–2761.

Dragic, T., Litwin, V., Allaway, G.P., Martin, S.R., Huang, Y., Nagashima, K.A., Cayanan, C., Maddon, P.J., Koup, R.A., Moore, J.P., Paxton, W.A., 1996. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381 (6584), 667–673.

Feng, Y., Broder, C.C., Kennedy, P.E., Berger, E.A., 1996. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272 (5263), 872–877.

Fouchier, R.A., Groenink, M., Kootstra, N.A., Tersmette, M., Huisman, H.G., Miedema, F., Schuitemaker, H., 1992. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J. Virol. 66 (5), 3183–3187.

Hartley, O., Klasse, P.J., Sattentau, Q.J., Moore, J.P., 2005. V3: HIV's switch-hitter. AIDS Res. Hum. Retroviruses 21 (2), 171–189.

Hoffman, T.L., Doms, R.W., 1999. HIV-1 envelope determinants for cell tropism and chemokine receptor use. Mol. Membr. Biol. 16 (1), 57–65.

Hoffman, N.G., Seillier-Moiseiwitsch, F., Ahn, J., Walker, J.M., Swanstrom, R., 2002. Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. J. Virol. 76 (8), 3852–3864.

Huang, C.C., Tang, M., Zhang, M.Y., Majeed, S., Montabana, E., Stanfield, R.L., Dimitrov, D.S., Korber, B., Sodroski, J., Wilson, I.A., Wyatt, R., Kwong, P.D., 2005. Structure of a V3-containing HIV-1 gp120 core. Science 310 (5750), 1025–1028.

Huang, C.C., Lam, S.N., Acharya, P., Tang, M., Xiang, S.H., Hussan, S.S., Stanfield, R.L., Robinson, J., Sodroski, J., Wilson, I.A., Wyatt, R., Bewley, C.A., Kwong, P.D., 2007. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 317 (5846), 1930–1934.

Huang, W., Toma, J., Fransen, S., Stawiski, E., Reeves, J.D., Whitcomb, J.M., Parkin, N., Petropoulos, C.J., 2008. Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein. J. Virol. 82 (11), 5584–5593.

Hung, C.S., Vander Heyden, N., Ratner, L., 1999. Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization. J. Virol. 73 (10), 8216–8226.

Hwang, S.S., Boyle, T.J., Lyerly, H.K., Cullen, B.R., 1991. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 253 (5015), 71–74.

Im, W., Beglov, D., Roux, B., 1998. Continuum solvation model: computation of electrostatic forces from numerical solutions to the Poisson–Boltzmann equation. Comput. Phys. Commun. 111, 59–75.

Jensen, M.A., Li, F.S., van 't Wout, A.B., Nickle, D.C., Shriner, D., He, H.X., McLaughlin, S., Shankarappa, R., Margolick, J.B., Mullins, J.I., 2003. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J. Virol. 77 (24), 13376–13388.

Jensen, M.A., Coetzer, M., van 't Wout, A.B., Morris, L., Mullins, J.I., 2006. A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences. J. Virol. 80 (10), 4698–4704.

Jo, S., Vargyas, M., Vasko-Szedlar, J., Roux, B., Im, W., 2008. PBEQ-Solver for online visualization of electrostatic potential of biomolecules. Nucleic Acids Res. 36, W270–W275 (Web Server issue).

Johnston, E.R., Zijenah, L.S., Mutetwa, S., Kantor, R., Kittinunvorakoon, C., Katzenstein, D.A., 2003. High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. J. Virol. 77 (13), 7682–7688.

Kajumo, F., Thompson, D.A., Guo, Y., Dragic, T., 2000. Entry of R5X4 and X4 human immunodeficiency virus type 1 strains is mediated by negatively charged and tyrosine residues in the amino-terminal domain and the second extracellular loop of CXCR4. Virology 271 (2), 240–247.

Karlsson, A., Parsmyr, K., Sandstrom, E., Fenyo, E.M., Albert, J., 1994. MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J. Clin. Microbiol. 32 (2), 364–370.

Kassaye, S., Johnston, E., McColgan, B., Kantor, R., Zijenah, L., Katzenstein, D., 2009. Envelope coreceptor tropism, drug resistance, and viral evolution among subtype C HIV-1-infected individuals receiving nonsuppressive antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 50 (1), 9–18.

Labrosse, B., Treboute, C., Brelot, A., Alizon, M., 2001. Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor. J. Virol. 75 (12), 5457–5464.

Maas, J.J., Gange, S.J., Schuitemaker, H., Coutinho, R.A., van Leeuwen, R., Margolick, J.B., 2000. Strong association between failure of T cell homeostasis and the syncytium-inducing phenotype among HIV-1-infected men in the Amsterdam Cohort Study. AIDS 14 (9), 1155–1161.

Maeda, Y., Yusa, K., Harada, S., 2008. Altered sensitivity of an R5X4 HIV-1 strain 89.6 to coreceptor inhibitors by a single amino acid substitution in the V3 region of gp120. Antiviral Res. 77 (2), 128–135.

McCormack, G.P., Glynn, J.R., Crampin, A.C., Sibande, F., Mulawa, D., Bliss, L., Broadbent, P., Abarca, K., Ponnighaus, J.M., Fine, P.E., Clewley, J.P., 2002. Early evolution of the human immunodeficiency virus type 1 subtype C epidemic in rural Malawi. J. Virol. 76 (24), 12890–12899.

Michael, N.L., Chang, G., Louie, L.G., Mascola, J.R., Dondero, D., Birx, D.L., Sheppard, H.W., 1997. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat. Med. 3 (3), 338–340.

Michler, K., Connell, B.J., Venter, W.D., Stevens, W.S., Capovilla, A., Papathanasopoulos, M.A., 2008. Genotypic characterization and comparison of full-length envelope glycoproteins from South African HIV type 1 subtype C primary isolates that utilize CCR5 and/or CXCR4. AIDS Res. Hum. Retroviruses 24 (5), 743–751.

Milich, L., Margolin, B.H., Swanstrom, R., 1997. Patterns of amino acid variability in NSI-like and SI-like V3 sequences and a linked change in the CD4-binding domain of the HIV-1 Env protein. Virology 239 (1), 108–118.

Miller, E.D., Duus, K.M., Townsend, M., Yi, Y., Collman, R., Reitz, M., Su, L., 2001. Human immunodeficiency virus type 1 IIIB selected for replication in vivo exhibits increased envelope glycoproteins in virions without alteration in coreceptor usage: separation of in vivo replication from macrophage tropism. J. Virol. 75 (18), 8498–8506.

Morris, L., Cilliers, T., Bredell, H., Phoswa, M., Martin, D.J., 2001. CCR5 is the major coreceptor used by HIV-1 subtype C isolates from patients with active tuberculosis. AIDS Res. Hum. Retroviruses 17 (8), 697–701.

Mosier, D.E., 2009. How HIV changes its tropism: evolution and adaptation? Curr. Opin. HIV AIDS 4 (2), 125–130.

Nabatov, A.A., Pollakis, G., Linnemann, T., Kliphuis, A., Chalaby, M.I., Paxton, W.A., 2004. Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies. J. Virol. 78 (1), 524–530.

Ndung'u, T., Sepako, E., McLane, M.F., Chand, F., Bedi, K., Gaseitsiwe, S., Doualla-Bell, F., Peter, T., Thior, I., Moyo, S.M., Gilbert, P.B., Novitsky, V.A., Essex, M., 2006. HIV-1 subtype C in vitro growth and coreceptor utilization. Virology 347 (2), 247–260.

Nolan, K.M., Jordan, A.P., Hoxie, J.A., 2008. Effects of partial deletions within the human immunodeficiency virus type 1 V3 loop on coreceptor tropism and sensitivity to entry inhibitors. J. Virol. 82 (2), 664–673.

Ogert, R.A., Lee, M.K., Ross, W., Buckler-White, A., Martin, M.A., Cho, M.W., 2001. N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism. J. Virol. 75 (13), 5998–6006.

Papathanasopoulos, M.A., Hunt, G.M., Tiemessen, C.T., 2003. Evolution and diversity of HIV-1 in Africa—a review. Virus Genes 26 (2), 151–163.

Pastore, C., Nedellec, R., Ramos, A., Pontow, S., Ratner, L., Mosier, D.E., 2006. Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J. Virol. 80 (2), 750–758.

Patel, M.B., Hoffman, N.G., Swanstrom, R., 2008. Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins. J. Virol. 82 (2), 903–916.

Ping, L.H., Nelson, J.A., Hoffman, I.F., Schock, J., Lamers, S.L., Goodman, M., Vernazza, P., Kazembe, P., Maida, M., Zimba, D., Goodenow, M.M., Eron Jr., J.J., Fiscus, S.A., Cohen, M.S., Swanstrom, R., 1999. Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. J. Virol. 73 (8), 6271–6281.

Pollakis, G., Kang, S., Kliphuis, A., Chalaby, M.I., Goudsmit, J., Paxton, W.A., 2001. N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J. Biol. Chem. 276 (16), 13433–13441.

Pollakis, G., Abebe, A., Kliphuis, A., Chalaby, M.I.M., Bakker, M., Mengistu, Y., Brouwer, M., Goudsmit, J., Schuitemaker, H., Paxton, W.A., 2004. Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals. J. Virol. 78 (6), 2841–2852.

Pond, S.L., Frost, S.D., 2005. Datamonkey: rapid detection of selective pressure on individual sites of codon alignments. Bioinformatics 21 (10), 2531–2533.

Pond, S.L., Frost, S.D., Muse, S.V., 2005. HyPhy: hypothesis testing using phylogenies. Bioinformatics 21 (5), 676–679.

Rana, S., Besson, G., Cook, D.G., Rucker, J., Smyth, R.J., Yi, Y., Turner, J.D., Guo, H.H., Du, J.G., Peiper, S.C., Lavi, E., Samson, M., Libert, F., Liesnard, C., Vassart, G., Doms, R.W., Parmentier, M., Collman, R.G., 1997. Role of CCR5 in infection of primary macrophages and lymphocytes by macrophage-tropic strains of human immunodeficiency virus: resistance to patient-derived and prototype isolates resulting from the delta ccr5 mutation. J. Virol. 71 (4), 3219–3227.

Raymond, S., Delobel, P., Mavigner, M., Ferradini, L., Cazabat, M., Souyris, C., Sandres-Saune, K., Pasquier, C., Marchou, B., Massip, P., Izopet, J., 2010. Prediction of HIV type 1 subtype C tropism by genotypic algorithms built from subtype B viruses. J. Acquir. Immune Defic. Syndr. 53 (2), 167–175.

Reitz Jr., M.S., Hall, L., Robert-Guroff, M., Lautenberger, J., Hahn, B.M., Shaw, G.M., Kong, L.I., Weiss, S.H., Waters, D., Gallo, R.C., et al., 1994. Viral variability and serum antibody response in a laboratory worker infected with HIV type 1 (HTLV type IIIB). AIDS Res. Hum. Retroviruses 10 (9), 1143–1155.

Richman, D.D., Bozzette, S.A., 1994. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J. Infect. Dis. 169 (5), 968–974.

Rizzuto, C.D., Wyatt, R., Hernandez-Ramos, N., Sun, Y., Kwong, P.D., Hendrickson, W.A., Sodroski, J., 1998. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 280 (5371), 1949–1953.

Scarlatti, G., Tresoldi, E., Bjorndal, A., Fredriksson, R., Colognesi, C., Deng, H.K., Malnati, M.S., Plebani, A., Siccardi, A.G., Littman, D.R., Fenyo, E.M., Lusso, P., 1997. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat. Med. 3 (11), 1259–1265.

Schuitemaker, H., Koot, M., Kootstra, N.A., Dercksen, M.W., de Goede, R.E., van Steenwijk, R.P., Lange, J.M., Schattenkerk, J.K., Miedema, F., Tersmette, M., 1992. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J. Virol. 66 (3), 1354–1360.

Shioda, T., Levy, J.A., Cheng-Mayer, C., 1991. Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature 349 (6305), 167–169.

Shioda, T., Oka, S., Ida, S., Nokihara, K., Toriyoshi, H., Mori, S., Takebe, Y., Kimura, S., Shimada, K., Nagai, Y., et al., 1994. A naturally occurring single basic amino acid substitution in the V3 region of the human immunodeficiency virus type 1 env protein alters the cellular host range and antigenic structure of the virus. J. Virol. 68 (12), 7689–7696.

Singh, A., Page, T., Moore, P.L., Allgaier, R.L., Hiramen, K., Coovadia, H.M., Walker, B.D., Morris, L., Ndung'u, T., 2009. Functional and genetic analysis of coreceptor usage by dualtropic HIV-1 subtype C isolates. Virology 393 (1), 56–67.

Tsibris, A.M., Sagar, M., Gulick, R.M., Su, Z., Hughes, M., Greaves, W., Subramanian, M., Flexner, C., Giguel, F., Leopold, K.E., Coakley, E., Kuritzkes, D.R., 2008. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J. Virol. 82 (16), 8210–8214.

Wang, J., Babcock, G.J., Choe, H., Farzan, M., Sodroski, J., Gabuzda, D., 2004. N-linked glycosylation in the CXCR4 N-terminus inhibits binding to HIV-1 envelope glycoproteins. Virology 324 (1), 140–150.

Westervelt, P., Trowbridge, D.B., Epstein, L.G., Blumberg, B.M., Li, Y., Hahn, B.H., Shaw, G.M., Price, R.W., Ratner, L., 1992. Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo. J. Virol. 66 (4), 2577–2582.

Zhang, H., Hoffmann, F., He, J., He, X., Kankasa, C., West, J.T., Mitchell, C.D., Ruprecht, R.M., Orti, G., Wood, C., 2006. Characterization of HIV-1 subtype C envelope glycoproteins from perinatally infected children with different courses of disease. Retrovirology 3, 73.

Zhang, H., Rola, M., West, J.T., Tully, D.C., Kubis, P., He, J., Kankasa, C., Wood, C., 2010. Functional properties of the HIV-1 subtype C envelope glycoprotein associated with mother-to-child transmission. Virology 400 (2), 164–174.